Quantcast

Latest Denosumab Stories

2014-09-15 16:29:02

Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia(®) (denosumab) for eight years enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic T-scores (>-2.5) at the lumbar spine and...

2014-09-15 16:28:40

Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from several exploratory analyses of the Phase 2 study evaluating romosozumab in postmenopausal women with low bone mineral density (BMD). Romosozumab is an investigational bone-forming agent that is designed to work by inhibiting the protein sclerostin, thereby...

2014-09-10 08:32:41

Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab THOUSAND OAKS, Calif., Sept. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present data from multiple Prolia(®) (denosumab) and romosozumab study analyses at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting being held in Houston, Sept. 12-15, 2014. The data that will be...

2014-05-27 16:25:23

New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 27, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced data from several studies of both pipeline and marketed products will be presented at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30-June 3 in Chicago. The research that will...

2013-12-03 11:15:50

Findings to help physicians guide treatment options for women A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research’s annual meeting. Researchers performed a retrospective chart review and...

2013-09-12 23:18:41

Transparency Market Research published new "Global Osteoporosis Drug Market- China Industry Analysis, Size, Share, Growth, Trends and Forecast, 2010 - 2015" market research report to its report store. Browse the report with TOC; visit http://www.transparencymarketresearch.com/osteoporosis-drug-market.html. Albany, New York (PRWEB) September 12, 2013 According to Transparency Market Research “Osteoporosis Drug Market- Global and China market analysis, size, trends and forecast...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related